PCSK9 and inherited lipid metabolism disorder: The 2019 guidelines of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) for the management of dyslipidaemias in LEAD patients recommend a maximum acceptable dose of a high-intensity statin (atorvastatin ≥ 40 mg or rosuvastatin ≥ 20 mg), accompanied by ezetimibe or a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, if necessary, in order to diminish the risk of atherosclerotic cardiovascular disease events [2].